1.Age < 18 years <br/ >2.Not willing to enter the study <br/ >3.Known hypersensitivity to colchicine. <br/ >4.Inflammatory bowel disease, chronic diarrhea or malabsorption <br/ >5.Previous neuromuscular disease <br/ >6.Cirrhosis, active chronic hepatitis or severe hepatic disease defined by SGOT or SGPT levels three times above the normal upper limit <br/ >7.Treatment with immunosuppressive agents, corticosteroids or interleukine-1 antagonists for 6 months before inclusion <br/ >8.Pregnant or breastfeeding females <br/ >9.Patient currently taking colchicine for indications other than SARS-CoV-2 infection prophylaxis <br/ >10.History of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia) <br/ >11.Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study <br/ >

1.Age < 18 years <br/ >2.Not willing to enter the study <br/ >3.Known hypersensitivity to colchicine. <br/ >4.Inflammatory bowel disease, chronic diarrhea or malabsorption <br/ >5.Previous neuromuscular disease <br/ >6.Cirrhosis, active chronic hepatitis or severe hepatic disease defined by SGOT or SGPT levels three times above the normal upper limit <br/ >7.Treatment with immunosuppressive agents, corticosteroids or interleukine-1 antagonists for 6 months before inclusion <br/ >8.Pregnant or breastfeeding females <br/ >9.Patient currently taking colchicine for indications other than SARS-CoV-2 infection prophylaxis <br/ >10.History of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia) <br/ >11.Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study <br/ >

N/A

N/A

1.Age < 18 years <br/ >2.Not willing to enter the study <br/ >3.Known hypersensitivity to colchicine. <br/ >4.Inflammatory bowel disease, chronic diarrhea or malabsorption <br/ >5.Previous neuromuscular disease <br/ >6.Cirrhosis, active chronic hepatitis or severe hepatic disease defined by SGOT or SGPT levels three times above the normal upper limit <br/ >7.Treatment with immunosuppressive agents, corticosteroids or interleukine-1 antagonists for 6 months before inclusion <br/ >8.Pregnant or breastfeeding females <br/ >9.Patient currently taking colchicine for indications other than SARS-CoV-2 infection prophylaxis <br/ >10.History of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia) <br/ >11.Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study <br/ >

1.Age < 18 years <br/ >2.Not willing to enter the study <br/ >3.Known hypersensitivity to colchicine. <br/ >4.Inflammatory bowel disease, chronic diarrhea or malabsorption <br/ >5.Previous neuromuscular disease <br/ >6.Cirrhosis, active chronic hepatitis or severe hepatic disease defined by SGOT or SGPT levels three times above the normal upper limit <br/ >7.Treatment with immunosuppressive agents, corticosteroids or interleukine-1 antagonists for 6 months before inclusion <br/ >8.Pregnant or breastfeeding females <br/ >9.Patient currently taking colchicine for indications other than SARS-CoV-2 infection prophylaxis <br/ >10.History of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia) <br/ >11.Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study <br/ >